Inotiv Reports Q3 Fiscal 2025 Revenue Increase of 23.5%

WEST LAFAYETTE, Ind. — August 6, 2025 — Leads & Copy — Inotiv, Inc. (Nasdaq: NOTV) announced its financial results for the third quarter of fiscal year 2025, which ended June 30, 2025. Revenue for the quarter increased by 23.5% to $130.7 million, while year-to-date revenue rose by 4.0% to $374.9 million.

Robert Leasure Jr., President and CEO, noted progress toward financial goals outlined in May, with revenue and margins improving over the second quarter. DSA net awards for Q3 FY 2025 increased 25% year-over-year, driven by integration, optimization, and start-up investments.

The company remains focused on client satisfaction, monitoring operational data and client metrics to build a strong recurring client base.

Q3 FY 2025 Highlights:

Revenue: $130.7 million, up 23.5% from Q3 FY 2024.

Net Loss: $17.6 million, compared to $26.1 million in Q3 FY 2024.

Adjusted EBITDA: $11.6 million, compared to $0.1 million in Q3 FY 2024.

DSA backlog: $134.3 million as of June 30, 2025.

YTD FY 2025 Highlights:

Revenue: $374.9 million, up 4.0% from YTD FY 2024.

Net Loss: $60.1 million, compared to $90.0 million in YTD FY 2024.

Adjusted EBITDA: $22.1 million, compared to $12.8 million in YTD FY 2024.

Recent Developments:

The SEC concluded its investigation related to NHP importations, with no enforcement action recommended against the Company.

A $10.0 million accrual has been recorded for securities class action and shareholder derivative lawsuits, with an expected full recovery under existing insurance policies.

Beth A. Taylor, Chief Financial Officer, (765) 497-8381, beth.taylor@inotiv.com

Steve Halper, LifeSci Advisors, (646) 876-6455, shalper@lifesciadvisors.com

Source: Inotiv, Inc.

×

Welcome!

BiotechReporter.news is a Leads & Copy Publication

Leads & Copy is a Media “news tip” source, providing Industry Reporters story Leads, written as Publishable CP-style Copy.

By Subscribing you will receive Daily Biotech Story Leads via email 10:30 am Mon-Fri.